Document is current
Any future updates will be listed below
-
Authors
Alzua, Garazi Peña https://orcid.org/0000-0001-9139-9915
León, André Nicolás https://orcid.org/0000-0001-5926-8966
Yellin, Temima https://orcid.org/0009-0009-1907-0336
Bhavsar, Disha https://orcid.org/0000-0003-1564-3298
Loganathan, Madhumathi https://orcid.org/0000-0002-3751-8036
Bushfield, Kaitlyn
Brouwer, Philip J. M.
Rodriguez, Alesandra J.
Jeevan, Trushar
Webby, Richard https://orcid.org/0000-0002-4397-7132
Marizzi, Christine
Han, Julianna https://orcid.org/0000-0002-3402-2609
Ward, Andrew B. https://orcid.org/0000-0001-7153-3769
Duty, J. Andrew
Krammer, Florian https://orcid.org/0000-0003-4121-776X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93021C00014)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N39019C00051)
- License Information
-
More Information
Article History
Received: 7 July 2025
Accepted: 17 November 2025
First Online: 13 December 2025
Competing interests
: The Icahn School of Medicine at Mount Sinai has filed patent applications regarding the described H5 mAbs which list G.P.A., J.A.D. and F.K. as inventors. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines and influenza virus therapeutics which list F.K. as co-inventor and F.K. has received royalty payments from some of these patents. Mount Sinai has spun out a company, Castlevax, to develop SARS-CoV-2 vaccines. F.K. is co-founder and scientific advisory board member of Castlevax. F.K. has consulted for Merck, GSK, Sanofi, Curevac, Gritstone, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development. ABW has received royalty payments for the licensure of a prefusion coronavirus spike stabilization technology for which he is a co-inventor. A.B.W. is currently consulting for Third Rock Ventures and Merida Biosciences. J.H. and A.B.W. are consultants for Third Rock Ventures. The remaining authors declare no competing interests.
